Residency · Residency · Critical Care

Neurocritical Care: Status Epilepticus

Definitions

Status Epilepticus (SE)

Status epilepticus is one of the most time-sensitive neurological emergencies encountered in critical care, demanding immediate recognition and aggressive, protocol-driven management. The operational definition established by the International League Against Epilepsy (ILAE) in 2015 defines SE as seizure activity lasting 5 minutes or longer, or two or more seizures occurring without full recovery of consciousness between episodes. This threshold replaced the earlier definition of 30 minutes, which was recognized as far too long for clinical decision-making, as treatment delays of even minutes can have devastating consequences for neurological outcomes.

Convulsive status epilepticus (CSE) is the most readily recognized form, presenting with tonic-clonic motor activity accompanied by impaired consciousness. It constitutes a medical emergency requiring immediate intervention. Non-convulsive status epilepticus (NCSE) presents with electrographic seizure activity on electroencephalography without prominent motor manifestations and can only be definitively diagnosed through continuous EEG monitoring. Super-refractory status epilepticus (SRSE) represents the most treatment-resistant form, defined as seizure activity that continues for 24 hours or more after the onset of anesthetic therapy, including seizures that recur during attempted taper of anesthetic agents.

Classification by Stage

The staged classification of SE provides a framework for escalating treatment intensity in parallel with treatment resistance. Early SE, spanning 5 to 30 minutes, represents the benzodiazepine-responsive phase during which first-line agents have the highest probability of success. Established SE, from 30 to 60 minutes, indicates failure of benzodiazepine therapy and requires second-line antiseizure medications. Refractory SE (RSE) is defined by persistence despite adequate trials of two appropriately dosed medications, including at least one benzodiazepine. The final and most ominous stage, super-refractory SE, is defined by seizure persistence for 24 hours or more despite continuous anesthetic infusion.

Epidemiology

The incidence of status epilepticus ranges from 20 to 40 per 100,000 population per year, making it a relatively common neurological emergency. Mortality increases sharply with treatment resistance: CSE carries a mortality of 15 to 20 percent, RSE 30 to 50 percent, and SRSE up to 60 percent. The most common etiologies include medication non-compliance or subtherapeutic antiseizure drug levels (the most frequent cause in patients with known epilepsy), acute stroke, central nervous system infection, metabolic derangements, toxic ingestion, and traumatic brain injury.

Pathophysiology

Mechanisms of Sustained Seizure Activity

Understanding the pathophysiology of sustained seizure activity is essential because it directly explains the urgency of treatment and the phenomenon of progressive treatment resistance. During the initial phase of SE, excessive glutamate release drives sustained neuronal depolarization through activation of AMPA and NMDA receptors. As seizure activity continues, a critical molecular process unfolds: synaptic GABA-A receptors, the very targets of benzodiazepine therapy, are internalized from the neuronal surface membrane into the cytoplasm through clathrin-mediated endocytosis. This receptor trafficking occurs within 5 to 30 minutes of sustained seizure activity and is the primary mechanism underlying the development of benzodiazepine resistance.

Simultaneously, NMDA receptors undergo the opposite process, trafficking from intracellular stores to the synaptic membrane, resulting in increased excitatory neurotransmission and amplified excitotoxicity. This receptor trafficking explains the clinical observation that benzodiazepines become progressively less effective with each passing minute of untreated SE, providing the biological rationale for the imperative to treat early and with adequate doses.

Consequences of Prolonged SE

The consequences of prolonged SE extend from the cellular to the systemic level. Excitotoxic neuronal death results from massive calcium influx through NMDA receptors, leading to mitochondrial failure, activation of destructive enzymatic cascades, and ultimately apoptotic cell death. The systemic response to SE follows a biphasic pattern. During Phase 1, encompassing the first 30 minutes, a massive catecholamine surge produces a compensated state characterized by tachycardia, hypertension, and hyperglycemia. In Phase 2, beyond 30 minutes, physiological decompensation occurs with the development of hypotension, hypoglycemia, hyperthermia, cerebral edema, and renal failure from rhabdomyolysis. The guiding principle is that time is brain: each minute of ongoing SE increases the probability of permanent neurological injury and further reduces the likelihood of treatment success.

<image>Timeline diagram of status epilepticus pathophysiology and treatment stages. Horizontal axis: time from seizure onset (0 to >24 hours). Upper panel shows cellular/molecular changes: GABA-A receptor internalization curve (decreasing receptor density over time), NMDA receptor upregulation curve (increasing), and neuronal injury threshold line. Middle panel shows systemic changes: Phase 1 (compensated — BP up, glucose up, HR up) transitioning to Phase 2 (decompensated — BP down, glucose down, temperature up, acidosis). Lower panel shows treatment stages with specific medications at each tier: early SE (0-5 min: benzodiazepines), established SE (5-30 min: second-line AEDs), refractory SE (30-60 min: continuous infusions), super-refractory SE (>24 hrs: advanced therapies). Include success rates at each stage: benzodiazepines 60-70%, second-line 30-40%, anesthetics 25-30%.</image>

Management: Staged Approach

Stage 1: Immediate Stabilization (0-5 Minutes)

The initial management of SE follows the same airway, breathing, and circulation priorities that govern all emergency resuscitation. Airway patency must be ensured, supplemental oxygen provided, intravenous access established, and continuous cardiorespiratory monitoring initiated. A fingerstick glucose must be checked immediately, as hypoglycemia is a readily reversible cause of seizures; if glucose is below 60 mg/dL, 50 mL of dextrose 50 percent should be administered intravenously along with 100 mg of thiamine to prevent precipitation of Wernicke encephalopathy. Laboratory studies including electrolytes (sodium, calcium, magnesium, glucose), antiseizure drug levels, complete blood count, basic metabolic panel, liver function tests, toxicology screen, and arterial blood gas should be obtained simultaneously. The patient should be positioned safely, and nothing should be forced into the mouth.

Stage 2: First-Line — Benzodiazepines (5-20 Minutes)

Benzodiazepines are the definitive first-line treatment for SE, and their efficacy is time-dependent due to the progressive GABA-A receptor internalization described above. The RAMPART trial (2012) established that intramuscular midazolam is non-inferior to intravenous lorazepam for pre-hospital SE, with seizure cessation rates of 73 percent for IM midazolam versus 63 percent for IV lorazepam, the advantage of IM midazolam being attributable to faster administration without the need for IV access.

Intravenous lorazepam remains the preferred IV agent, dosed at 0.1 mg/kg (maximum 4 mg per dose), which may be repeated once at 5 minutes for a total maximum of 8 mg. Lorazepam's advantage over other IV benzodiazepines is its longer duration of antiseizure effect, lasting 12 to 24 hours compared to the brief CNS duration of diazepam or midazolam. Intravenous diazepam at 0.15 to 0.2 mg/kg (maximum 10 mg per dose) may be used as an alternative, though its short CNS duration necessitates follow-up with a longer-acting antiseizure drug. Intramuscular midazolam at 10 mg is the preferred route when IV access is not immediately available, with an onset of 3 to 5 minutes. Intranasal midazolam at 5 mg per nostril (0.2 mg/kg) is a useful alternative, particularly in pediatric settings. Rectal diazepam at 0.2 to 0.5 mg/kg provides another non-IV option.

The most critical principle at this stage is to administer an adequate dose early. Underdosing of benzodiazepines is the single most common error in SE management and directly contributes to treatment resistance by allowing additional time for GABA-A receptor internalization.

Stage 3: Second-Line — Established SE (20-40 Minutes)

If seizures persist after two adequate doses of benzodiazepines, second-line antiseizure medication should be started immediately. The ESETT trial (2019) provided definitive comparative evidence by randomizing patients with benzodiazepine-refractory SE to levetiracetam, fosphenytoin, or valproate, finding all three agents to be equally effective at approximately 50 percent seizure cessation each.

Levetiracetam is dosed at 60 mg/kg IV (maximum 4500 mg) infused over 15 minutes and has become the most commonly used second-line agent due to its favorable safety profile. It produces no hemodynamic effects, has minimal drug interactions, causes no hepatotoxicity, and is renally cleared, making it safe in patients with liver disease.

Fosphenytoin is the prodrug of phenytoin, dosed at 20 mg PE/kg IV at a maximum infusion rate of 150 mg PE/min. Free phenytoin levels should be monitored with a therapeutic range of 1 to 2 mcg/mL (free) or 10 to 20 mcg/mL (total). The most significant risks include hypotension, bradycardia, and cardiac arrhythmias, necessitating continuous ECG monitoring during infusion. Fosphenytoin is contraindicated in patients with second- or third-degree atrioventricular block or known cardiac conduction disease.

Valproic acid is dosed at 40 mg/kg IV (maximum 3000 mg) over 10 minutes and offers the advantage of broad-spectrum efficacy across multiple seizure types with minimal hemodynamic effects. Its risks include hepatotoxicity (particularly dangerous in patients with mitochondrial disease such as Alpers syndrome), pancreatitis, thrombocytopenia, and hyperammonemia. It is contraindicated in pregnancy due to teratogenicity and in liver disease.

The key clinical takeaway from the ESETT trial is that agent selection should be guided by patient comorbidities rather than by efficacy differences: avoid levetiracetam in severe renal failure, avoid valproate in liver disease or pregnancy, and avoid fosphenytoin in cardiac conduction disease.

Stage 4: Refractory SE — Continuous Infusions (>40 Minutes)

When SE persists despite adequate benzodiazepine and second-line therapy, the transition to continuous anesthetic infusions is required. This stage mandates endotracheal intubation for airway protection and initiation of continuous EEG monitoring, which is essential for titrating therapy to the electrographic treatment goal.

Midazolam is administered as a 0.2 mg/kg loading bolus followed by an infusion of 0.1 to 2 mg/kg/hr, titrated to the EEG goal of seizure suppression or burst-suppression. It offers rapid onset and easy titration but is limited by tachyphylaxis (diminishing effectiveness with continued use) and prolonged sedation due to accumulation.

Propofol is given as a 2 mg/kg loading bolus followed by an infusion of 30 to 200 mcg/kg/min. It provides rapid onset and offset with potent anticonvulsant activity, but carries the risk of propofol infusion syndrome. Creatine kinase, triglycerides, and lactate should be monitored, and the infusion should ideally be limited to less than 5 mg/kg/hr and less than 48 hours when possible. Notably, propofol may lower the seizure threshold upon withdrawal, necessitating gradual tapering.

Pentobarbital, the most potent of the continuous anesthetic agents, is loaded at 5 to 15 mg/kg followed by an infusion of 0.5 to 5 mg/kg/hr. It is reserved for the most refractory cases due to severe hemodynamic depression requiring vasopressor support in most patients, prolonged half-life resulting in recovery periods of days after discontinuation, and significant immunosuppression with increased infection risk.

Stage 5: Super-Refractory SE (>24 Hours of Anesthetic Infusion)

Super-refractory SE demands consideration of agents with alternative mechanisms of action and non-pharmacological interventions. Ketamine, an NMDA receptor antagonist, is administered at 1 to 5 mg/kg/hr and represents a particularly rational choice for SRSE because it targets the NMDA receptor upregulation that characterizes prolonged SE. Emerging evidence from case series demonstrates 50 to 60 percent response rates, and its favorable hemodynamic profile, theoretical neuroprotective properties, and lack of respiratory depression make it an attractive agent.

Additional antiseizure drug loading should be attempted with agents not yet tried, including lacosamide 400 mg IV, phenobarbital 20 mg/kg IV, or topiramate 200 to 400 mg via nasogastric tube. When an autoimmune etiology is suspected, immunotherapy with IV methylprednisolone, intravenous immunoglobulin, or plasmapheresis should be initiated. Therapeutic hypothermia to 32 to 35 degrees Celsius has been used based on case reports but lacks randomized trial data. Electroconvulsive therapy has been reported successful in case reports of SRSE. The ketogenic diet, typically initiated within 1 to 2 weeks, has shown benefit in case series through a mechanism that is not fully understood. Finally, surgical resection should be considered if a focal, identifiable, resectable lesion is present.

<image>Four-tiered treatment protocol for status epilepticus displayed as a descending staircase, with each step representing a treatment stage. Tier 1 (widest step, green): Benzodiazepines — IV lorazepam 0.1 mg/kg or IM midazolam 10 mg; success rate 60-70%; timestamp 0-5 minutes. Tier 2 (yellow): Second-line AEDs — three options side by side (levetiracetam 60 mg/kg, fosphenytoin 20 PE/kg, valproate 40 mg/kg) with ESETT trial annotation showing equivalence; success rate ~50%; timestamp 5-30 minutes. Tier 3 (orange): Continuous infusions — midazolam, propofol, or pentobarbital with EEG monitoring goal (seizure suppression vs. burst-suppression); requires intubation; success rate 25-30%; timestamp 30-60+ minutes. Tier 4 (red, narrowest step): Super-refractory — ketamine, immunotherapy, hypothermia, ketogenic diet, surgical evaluation; timestamp >24 hours. Each tier includes intubation status, EEG monitoring requirement, and escalation criteria.</image>

Non-Convulsive Status Epilepticus (NCSE)

Clinical Features

Non-convulsive status epilepticus represents one of the most underdiagnosed and diagnostically challenging conditions in the ICU. It presents as altered mental status ranging from subtle confusion to deep coma and is frequently misdiagnosed as metabolic encephalopathy, delirium, or a prolonged post-ictal state. Subtle motor signs may be present, including tonic eye deviation, nystagmus, facial twitching, or automatisms, but these are easily overlooked in a sedated, mechanically ventilated patient. Continuous EEG monitoring studies have revealed that 8 to 20 percent of comatose ICU patients have NCSE, a prevalence that underscores the critical importance of maintaining a high index of suspicion. Furthermore, after convulsive activity ceases in CSE, 48 percent of patients continue to have electrographic seizures (DeLorenzo et al.), emphasizing the need for post-CSE EEG monitoring.

Diagnosis

The diagnosis of NCSE requires continuous EEG monitoring. Electrographic criteria include evolving rhythmic or periodic patterns with a frequency exceeding 2.5 Hz, or patterns that demonstrate clinical or electrographic improvement in response to an IV benzodiazepine trial. Certain EEG patterns exist on the ictal-interictal continuum and their interpretation remains controversial, including generalized periodic discharges (GPDs) and lateralized periodic discharges (LPDs).

The benzodiazepine trial is a valuable diagnostic tool: administration of 1 to 2 mg lorazepam IV while monitoring the EEG, with electrographic improvement accompanied by clinical improvement, confirms the diagnosis of NCSE. If the EEG improves but there is no clinical change, the interpretation is less certain. The recommended duration of continuous EEG monitoring is a minimum of 24 hours in comatose patients and 48 hours in post-cardiac arrest patients.

Treatment

The treatment approach for NCSE follows the same staged framework as convulsive SE, though the degree of urgency is a matter of clinical debate. Because NCSE generally poses less immediate risk than CSE, clinicians must balance the potential harm of ongoing electrographic seizure activity against the risks of treatment, which may include sedation-related complications and the need for intubation. For this reason, management is generally less aggressive than for CSE.

Antiseizure drugs that minimize sedation, such as levetiracetam, valproate, and lacosamide, are preferred as initial therapy. Continuous anesthetic infusions are reserved for NCSE with evidence of ongoing clinical deterioration or persistent unambiguous electrographic seizure activity. The EEG goal for treated NCSE is typically seizure suppression rather than burst-suppression, which is generally reserved for convulsive SE or NCSE with an aggressive, worsening trajectory.

Autoimmune Encephalitis and Status Epilepticus

Recognition

Autoimmune encephalitis should be considered in any young adult presenting with new-onset refractory status epilepticus (NORSE) or febrile infection-related epilepsy syndrome (FIRES). These patients often have a prodromal phase characterized by psychiatric symptoms, behavioral changes, or fever before the onset of seizures. The most commonly identified antibodies include anti-NMDA receptor, anti-LGI1, anti-CASPR2, anti-GABA-B receptor, and anti-AMPA receptor antibodies. A critical clinical point is that initial antibody testing is often negative, and clinicians should not wait for serological confirmation before initiating immunotherapy in a patient with a clinical presentation suggestive of autoimmune encephalitis.

Treatment

First-line immunotherapy consists of IV methylprednisolone at 1 g/day for 5 days combined with intravenous immunoglobulin at 0.4 g/kg/day for 5 days or therapeutic plasmapheresis. Second-line agents include rituximab at 375 mg/m2 weekly for 4 doses and cyclophosphamide. Concurrent antiseizure drug therapy is administered, though seizures in autoimmune encephalitis are characteristically refractory to standard antiseizure medications. In cases of anti-NMDA receptor encephalitis, screening for ovarian teratoma is essential, as the encephalitis may be paraneoplastic and tumor resection is a necessary component of definitive treatment.

EEG Monitoring in the ICU

Indications for Continuous EEG

Continuous EEG monitoring has become an essential tool in the neurocritical care unit. Indications include unexplained altered mental status or coma, ongoing monitoring after the cessation of convulsive SE to detect persistent electrographic seizures, post-cardiac arrest for both prognostication and seizure detection, acute brain injury (traumatic brain injury, subarachnoid hemorrhage, stroke) with fluctuating consciousness, and monitoring of burst-suppression depth during anesthetic therapy for refractory SE.

EEG Patterns in Critical Illness

Several characteristic EEG patterns are encountered in critically ill patients. Generalized periodic discharges (GPDs) are associated with metabolic encephalopathy, anoxic injury, and SE, with prognostic significance that depends heavily on the clinical context. Lateralized periodic discharges (LPDs) typically indicate an acute structural lesion such as stroke or herpes simplex encephalitis and are associated with increased seizure risk. Burst-suppression, characterized by alternating periods of high-amplitude activity and relative electrocerebral silence, may represent deep endogenous coma or may be the pharmacological target during anesthetic management of RSE. Alpha coma, an unreactive alpha-frequency pattern in a comatose patient, carries a poor prognosis, particularly in the post-cardiac arrest setting. Electrographic seizures are characterized by evolving rhythmic activity with a definite beginning, evolution in frequency, morphology, and spatial field, and a definite end.

Key Clinical Pearls

• Time is brain in status epilepticus — GABA receptor internalization begins within minutes, making benzodiazepines progressively less effective; treat early and with adequate doses
• Underdosing of benzodiazepines is the most common error in SE management — give full weight-based doses
• IM midazolam 10 mg is non-inferior to IV lorazepam for pre-hospital SE (RAMPART trial) — do not delay for IV access
• ESETT trial showed equivalence of levetiracetam, fosphenytoin, and valproate as second-line agents — choose based on patient comorbidities
• NCSE is present in 8-20% of comatose ICU patients — order continuous EEG for unexplained altered mental status
• Always check for autoimmune etiology in new-onset refractory SE (NORSE), especially in young adults — initiate immunotherapy empirically
• Ketamine is emerging as an important agent for refractory and super-refractory SE due to its NMDA antagonism
• EEG monitoring is mandatory during continuous anesthetic infusions for RSE — clinical assessment alone is insufficient

References

1. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus — Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523.
2. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591-600.
3. Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103-2113.
4. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23.
5. Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): state of the art and perspectives. Epilepsia. 2018;59(4):745-752.

Read this lecture as Markdown